Capstan Therapeutics Secures $175M in Series B Financing with Forbion Investment
March 22, 2024, 3:31 am
Capstan Therapeutics, a biotechnology company on the cutting edge of in vivo cell reprogramming, has successfully closed a $175M oversubscribed Series B financing round. The funding was led by RA Capital Management, with participation from new investors like Johnson and Johnson Innovation and Mubadala Capital, as well as existing backers such as Bristol Myers Squibb and Novartis Venture Fund.
Forbion, a prominent European life sciences venture capital firm, made its mark on this investment by joining the financing round and appointing Nanna Luneborg, PhD, MBA, as a new member of Capstan's Board of Directors. Luneborg expressed excitement about the potential of Capstan's in vivo CAR-T therapy, which aims to revolutionize cell modification without the need for ex vivo manipulation.
Capstan's flagship product, CPTX2309, utilizes targeted lipid nanoparticles (tLNP) to deliver mRNA encoding for an anti-CD19 CAR to CD8-expressing T cells. This innovative approach seeks to reset the immune system by depleting B cells in both blood and lymphoid tissues, offering a promising solution for autoimmune disorders.
With the Series B financing, Capstan plans to advance CPTX2309 to early clinical proof-of-concept in autoimmune conditions and further develop its tLNP pipeline. The company's mission is to expand therapeutic options for patients by harnessing the power of in vivo RNA technologies, potentially impacting a wide range of diseases including oncology, fibrosis, and monogenic blood disorders.
Capstan's proprietary tLNP platform, combined with strategic partnerships and investor support, positions the company as a key player in the biotechnology landscape. The collaboration with Forbion underscores the growing interest and confidence in Capstan's innovative approach to cell therapy and in vivo reprogramming.
As Capstan continues to push the boundaries of biotechnology, the future looks bright for the company and its potential to transform patient care through groundbreaking therapies. Stay tuned for more updates on Capstan Therapeutics and its journey towards revolutionizing the treatment of complex diseases.
Forbion, a prominent European life sciences venture capital firm, made its mark on this investment by joining the financing round and appointing Nanna Luneborg, PhD, MBA, as a new member of Capstan's Board of Directors. Luneborg expressed excitement about the potential of Capstan's in vivo CAR-T therapy, which aims to revolutionize cell modification without the need for ex vivo manipulation.
Capstan's flagship product, CPTX2309, utilizes targeted lipid nanoparticles (tLNP) to deliver mRNA encoding for an anti-CD19 CAR to CD8-expressing T cells. This innovative approach seeks to reset the immune system by depleting B cells in both blood and lymphoid tissues, offering a promising solution for autoimmune disorders.
With the Series B financing, Capstan plans to advance CPTX2309 to early clinical proof-of-concept in autoimmune conditions and further develop its tLNP pipeline. The company's mission is to expand therapeutic options for patients by harnessing the power of in vivo RNA technologies, potentially impacting a wide range of diseases including oncology, fibrosis, and monogenic blood disorders.
Capstan's proprietary tLNP platform, combined with strategic partnerships and investor support, positions the company as a key player in the biotechnology landscape. The collaboration with Forbion underscores the growing interest and confidence in Capstan's innovative approach to cell therapy and in vivo reprogramming.
As Capstan continues to push the boundaries of biotechnology, the future looks bright for the company and its potential to transform patient care through groundbreaking therapies. Stay tuned for more updates on Capstan Therapeutics and its journey towards revolutionizing the treatment of complex diseases.